CD22 and acute lymphoblastic leukemia: Inotuzumab ozogamicin (InO) is a CD22-targeted ADC that has shown consistent efficacy and tolerability when combined with chemotherapy in CD22-positive B-cell precursor acute lymphoblastic leukemia (B-ALL), regardless of patient age, disease status, or treatment history.